Daily SPAC Update – March 4, 2025

by | Mar 4, 2025

Iris Acquisition (IRAA) + Liminatus Pharma Deal Vote. Watch for Late 10-Ks. Flag Ship (FSHP) Extends Outside Date to August 28, 2025

Boardroom Alpha SPAC Resources
Full SPAC Listing
SPAC SEC Filings
Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)

Daily SPAC Update

MERGER VOTES
IRAA – Iris Acquisition Corp Liminatus Pharma LLC
Liminatus is a clinical-stage biopharmaceutical company developing novel cancer therapies that exploit the body’s immune system to recognise and attack cancer cells. The development pipeline consists of chimeric antigen receptor (CAR)-T cell therapeutics, Guanylyl Cyclase C (GCC) cancer vaccine and CD47 immune checkpoint inhibitor.

SPAC LATE 10-K FILINGS
TETEF – Technology & Telecommunication Acquisition Corp : Late 10-K

SPAC VOTE RESULTS
BHAC – FOCUS IMPACT BH3 ACQUISITION CO * Deal Approved * 1,208,570 redeemed

OTHER SPAC NEWS
FSHP – FLAG SHIP ACQUISITION CORP * Merger Agreement Amendment

SEPARATE WARRANTS/RIGHTS
Mar 07: MAYWOOD ACQUISITION CORP (MAYA)

SPAC DEALS ANNOUNCED
Feb 28 | HLXB – Helix Acquisition Corp Ii + BridgeBio Oncology Therapeutics

ABOUT BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. Initially formed as a subsidiary of BridgeBio Pharma, Inc. (Nasdaq: BBIO), BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, visit bridgebiooncology.com.

YESTERDAY’S TOP SPAC GAINERS
3.56% ~ $ 6.23 | GLST – GLOBAL STAR ACQUISITION INC (Announced)
2.04% ~ $ 10.99 | ESHA – ESH ACQUISITION CORP (Pre-Deal)
.94% ~ $ 11.77 | BNIX – BANNIX ACQUISITION CORP (Pre-Deal)
.68% ~ $ 10.35 | CEP – CANTOR EQUITY PARTNERS INC (Pre-Deal)
.50% ~ $ 12.06 | DECA – DENALI CAPITAL ACQUISITION CORP (Announced)

YESTERDAY’S TOP SPAC LOSERS
-7.11% ~ $ 3.66 | BOWN – BOWEN ACQUISITION CORP (Announced)
-1.45% ~ $ 10.89 | HLXB – HELIX ACQUISITION CORP II (Announced)
-1.35% ~ $ 10.95 | CCIR – COHEN CIRCLE ACQUISITION CORP I (Pre-Deal)
-1.23% ~ $ 12.00 | MSSA – METAL SKY STAR ACQUISITION CORP (Pre-Deal)
-1.16% ~ $ 11.95 | EVGR – EVERGREEN CORP (Announced)

LATEST SPAC IPO PERFORMANCE
Feb 27 |  | LOKV – Live Oak Acquisition Corp. V
Feb 27 |  | NHIC – NewHold Investment Corp. III
Feb 27 |  | FERA – Fifth Era Acquisition Corp I
Feb 26 |  | RAC – Rithm Acquisition Corp.
Feb 12 | $ 10.13 | MAYA – Maywood Acquisition Corp.
Feb 12 | $ 10.04 | AACB – Artius II Acquisition Inc.
Feb 10 | $ 10.06 | ATII – Archimedes Tech SPAC Partners II Co.
Feb 06 | $ 10.02 | KFII – K GROWTH ACQUISITION CORP. II

Recent Analysis

Daily SPAC Update – March 25, 2025

Newbury Street and DT Cloud Extend with $5.7M and $20M in Redemptions. Compass Digital Extension Vote Set. Concord Gets New Auditor. Winvest Delisting.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.